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ABSTRACT 
Salicylic acid was applied topically to the skin of 
rabbits and humans in order to study the pharmacokinetics of 
percutaneous absorption, and the effects of formulation and 
application variables on the rate and extent of absorption. 
Drug samples incorporated into hydrophilic ointment (USP} 
and hydrophilic ointment containing 10% urea, were applied 
to the shaved abdominal areas of female New Zealand rabbits 
for either four or eight hours. Drug samples used for the 
human studies were taken up in either hydrophilic ointment 
or in a polyethylene glycol/water solution. Blood samples 
were drawn from the rabbits over a twenty-four hour period 
and from humans over an eight-hour period. Absorption of 
salicylic acid was determined by fluorometric analysis. 
Pharmacokinetic analysis of (blood) data resulted from two 
treatments: the Wagner-Nelson methods; and a computerized, 
non-linear, least squares regression program NONLIN. 
The systemic absorption of salicylic acid from 
hydrophilic ointment was substantial in rabbits; however, 
incorporation of urea, 10% (w/w) 
effected no significant change. 
into the test ointment 
The effect of ointment 
contact time on serum levels showed that the absorption 
process was essentially complete within six hours. The 
elimination curve for salicylic acid applied to animals fed 
ii. 
during the test period exhibited an interesting and very 
substantial secondary peak not seen in fasted animals. The 
second peak may be due to biliary recycling. 
The systemic absorption of salicylic acid from 
polyethylene glycol/water solution applied to human skin was 
negligible, suggesting the formation of a salicylate-glycol 
complex. Plasma concentrations resulting from the 
application of salicylic acid in hydrophylic ointment to the 
intact skin of humans were less than 1 mg. However 
absorption from the sam~ system was increased considerably 
by disrupting the stratum corneum at the site of ointment 
application. 
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I. OBJECTIVES 
Topical application of salicylic acid preparations is a 
well established practice in dermatology. Of particular 
importance has been their use in the long term treatment of 
psoriasis. The literature is replete with reports of 
systemic salicylate toxicity, including fatalities, 
associated with the topical application of salicylic acid 
(1-5). In these cases considerable quantities of drug were 
applied to large areas of skin, in which disease had 
disrupted the barrier properties of the st~~l!fil £Orneu~L and 
for which occlusive therapy was considered appropriate. 
There is very little information available regarding 
either the rate or extent of systemic absorption of 
topically applied salicylic acid. Experimental procedures 
reported in the literature which deal with the percutaneous 
absorption of topically applied salicylic acid have not 
followed appropriate pharmacokinetic sampling methods; 
therefore, conclusions regarding bioavailability (i.e., the 
rate and extent of absorption) cannot be drawn. 
Characterization of the pharmacokinetic parameters 
describing the systemic absorption of percutaneously applied 
salicylic acid is important for two reasons: first, it would 
provide information regarding the pharmacokinetics of a drug 
administered by a topical deliver y system; and in addition, 
by characterizing t he rate and extent of systemic absorption 
of salicylic acid, it may be possible to decrease the 
potential hazards faced by patients exposed to long term 
topical salicylate therapy. 
The purpose of this project is therefore to study the 
systemic absorption of percutaneously applied salicylic 
acid, in rabbits as an animal model, and humans. The second 
objective is to examine the effect of formulation and 
application variables on the absorption of topically applied 
salicylic acid. Finally, it is planned to use salicylic 
acid to study the pharmacokinetcs of percutaneous 
absorption. , 
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II. INTRODUCTION 
A. · The ·Skin, Anatomy, and Physiology 
Skin, the largest organ of the body, consists of three 
anatomically distinct layers; the epidermis, the dermis, and 
the subcutaneous fat layer. The epidermis is a relatively 
thin, non-vascular, outer layer, which functions primarily 
as a barrier to the movement of material either into or out 
of the body. It may be subdivided into four layers, in 
ascending order; the stra1~~ germanitivumi the §1ra1y~ 
SEinosum, the stratum gran~l.2..§~~i and the st~tu~ CO.£!!.g~~~ 
The cells of each layer are formed from those of the 
p:i;eceding 
c•ll:s of 
layer beginning as the columnar, nucleated viable 
the stratu~ ~rmanitivumi and becoming the 
flattened, denucleated, dead cells of the stratum £Q£a§~~~ 
Dtiring this process the water content changes from about 70% 
td approximately 20, and the pH changes from about seven to 
four or five. In addition, keratin formation occurs from 
the cross-linking of poly-peptide chains by "peptide, and 
disulfide cysteine linkages", resulting in the hydrophobic, 
insoluble substance of the st£atum corneum. 
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The epidermis is connectad to the dermis by a series of 
cohelike ridges or papillae. The dermis consists primarily 
of a network of densely packed, non-cellular, collagen and 
elastin fibers. It functions as a supportive system for 
both blood and lymph vessels as well as for muscle and nerve 
fibers. In addition, the dermis contains eccrine, sweat, 
and sebaceous glands and numerous hair follicles. It varies 
in thickness from three to five mm., has a pH of about 7.1 
to 7.3 and contains 603 to 70% water. 
Beneath the dermis lies the subcutaneous fat layer 
which may be of varied thickness, functioning as the 
insulation and shock absorber for the internal organs of the 
body. 
Several excellent reviews of the complete anatomy and 
physiology of the skin have been published (6-8). 
B. Barrier Function of the St~tum Corneum 
The epidermis, more specifically the stratum £.Q~ggy~L 
is generally recognized as the major barrier to the systemic 
absorption of drugs applied topically. Disruption of the 
integrity of the st~tu~ £Or.lliU!fil has been shown to increase 
the diffusion of phenol and of strontium chloride (9,10). 
Disease states such as exfoliative dermatitis and psoriasis 
increase the _diffusion rates of sodium, zinc chloride, 
ammoniated mercury, and testosterone (11). The low 
permeability of the stratum corneum compared to the viable 
layers of the epidermis (10-9 to 10-13 cm2 sec-1 as compared 
to 10-6 cm2 sec-1) (12), characterize this layer as the 
principle barrier to diffusion. Through sequential 
stripping of the stratum £Q.£.!!§ill!! with adhesive tape, Blank 
(13) showed that its barrier properties remained intact 
4 
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until the lowest layers were removed. Scheuplein (14) and 
Idson (15) have used these data and electron micrographs to 
characterize the entire stratum corneum as a homogeneous 
barrier to penetration. 
C~ Routes of Percutaneous Absorption 
1. Transepidermal Absorption 
Transepidermal absorption, which refers to absorption 
thtough the st~tum corneul!!.L may be subdivided into two 
categories, transcellular and intercellular. Transcellular 
di~fusion represents the major route for the absorption of 
most substances. 
Electron micrographs of the stratum corneum (16) reveal 
that keratin consists of distinct protein filaments 
surrounded by areas of lipid material so that separate lipid 
and polar regions exist within this layer. Lipid soluble 
and water soluble substances are thought to partition into 
and then diffuse through either the lipid or polar region 
depending 
parallel. 
on their relative affinities (14) creating two 
routes for transcellular diffusion through the 
stratum corneum. 
Although the extent to which intercellular diffusion 
occurs has not been accurately determined, Scheuplein (17) 
cites the small intercellular volume available compared to 
that of the total stratum corneUJ!li electron micrographs 
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( 
sliowing extensive intercellular contact, and the existence 
of viscous, keratinous by-products within the intercellular 
spaces as factors limiting the importance of this route. 
2. Transappendageal Absorption 
Transappendageal 
of material through 
absorption refers to the penetration 
the eccrine and sweat glands and the 
pilo-sebaceous system, i.e., the sebaceous glands and hair 
follicles. The contribution made to the overall absorption 
p~ocess by 
skin they 
the . skin's 
these appendages is limited~ since the area of 
represent accounts for only about one percent of 
total surface area (18). For steady-state 
diffusion of most small, non-polar substances the role of 
transappendageal pathways is considered to be minimal. 
Before reaching the steady state, however, diffusion through 
the strat!!]l corneum exhibits a lag period, during which the 
transappendageal route may offer an early "shunt" pathway 
(6, 7) 
Scheuplein et al~ (19) has shown that for large polar 
molecules, (for example, steroids), transappendageal 
diffusion may ' offer the primary mechanism for systemic 
absorption. As diffusion through the stratum £Q~Q~ 
decreases, the importance of "shunt" diffusion increases, 
since the number of appendages within the area remains 
constant. As a result, the ratio of material diffusing 
through appendages to that pass i ng transepidermally will 
6 
increase. 
D. Salicylic Acid 
1. General Principles 
Salicylic acid, ortho-hydroxybenzoic acid, has the 
chemical formula C,H~O~, and a molecular weight of 138.12. 
It is found in the form of esters in several plants, notably 
in willow bark as salicin and in wintergreen as methyl 
salicylate. Today all salicylic acid is produced 
synthetically by heating sodium phenolate with carbon 
dioxide under pressure, a process developed by Kolbe and 
Lautemann in the mid nineteenth century. (20) 
Salicylic acid is available in either crystal or 
crystalline powder form. One gram dissolves in 460 ml. of 
water, 15 ml. of boiling water and 2.7 ml. of alcohol. The 
saturated aqueous solution has a pH of about 2.4 and the 
drug has a pkA of 3.3. 
2. Pharmacokinetics of Salicylic Acid 
Following absorption, salicylic acid is rapidly 
distributed throughout body tissue and transcellular fluid. 
The highest concentrations are found in plasma, renal 
cortex, liver, heart, and lung. The lowest concentrations 
in the brain and skeletal muscle. It can be detected in 
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synovial, spinal and peritoneal fluid, saliva and milk. 
salicylic acid is able to cross the placental barrier (21) • 
Salicylic acid in plasma is 50% to 80% protein bound, 
largely to albumin (22). The volume of distribution varies 
with dose, at higher levels the proportion bound to plasma 
protein decreases and the apparent volume of distribution 
increases. 
Salicylic acid is eliminated from the body by renal 
excretion of the unchanged drug or its metabolites. 
conjugation with glycine yields salicyluric acid (SU) • 
Conjugation with glucuronic acid yields salicylacyl 
glucuronide and salicyl phenolic glucuronide (SAG and SPG 
respectively). A fourth minor metabolite gentisic acid, 
(GA) is formed by oxidation (23). 
The reported half-lives of salicylates in adults range 
from 2.4 hours at a therapeutic dose (0.3 grams per day) to 
nineteen 
day) (24). 
increasing 
producing 
hours at higher levels (greater than ten grams per 
Levy has shown that an increasing half-life with 
dose is due to saturation of the pathways 
SU and SPG {25). The rates of formation of these 
metabolites may be described using Michaelis-Menton 
kinetics. Cummings and Martin (26) have calculated the 
threshold for saturation of SU formation to be 276 mg. 
salicylic acid in the body. Below this level overall 
elimination appears to follow first order kinetics. At 
higher levels where SU and SAG formation is limited, the 
overall eliminati on is occuring by parallel zero and first 
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order processes. When very high levels of salicylic acid 
are present, SU and SPG formation accounts for a very small 
portion of total elimination and the overall process appears 
to be first order (25, 27) • 
Levy (23) has characterized the overall elimination of 
salicylic acid by the following equation in which 
elimination rate constants for SU and SAG are replaced by 
their appropriate Michaelis - Menton terms: 
V SA 
dQ SPG b 
= - K SA 
dt K + SA 
m b 
V SA 
SU b 
K + SA 
m b 
Equation (1) 
Where 
K is equal to k sa + k sag + k ga 
k sa is the first order elimination rate 
constant of SA 
k sag is the first order elimination rate 
constant of GA 
k ga is the first order elimination rate 
of GA 
V is the theoretical maximal rate of formation 
obtainable from either Michaelis-Menton or 
Lineweaver-Burke plots 
SA body is the salicylic acid concentration 
in the body 
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E. Equations Governing Diffusion 
Topically applied drugs penetrate the skin by passive 
diffusion .. For conditions where the barrier provides the 
limiting step to diffusion, the steady state rate for 
diffusion may be described in terms of Fick's First Law; 
dQ dC 
= -DA 
dt dx 
Equation (2) 
Where 
dQ/dt is the steady state rate of diffusion 
D is the diffusion coefficient 
expressed as the amount of material diffusing 
per unit time per unit area, 
A is the surface area 
dC/dx describes an activity or concentration 
gradient where C is concentration and 
x is distance .. 
If D is assumed constant for a given system of penetrant and 
membrane, and A is constant then the driving force in 
passive diffusion is dc/dx, the concentration gradient. 
An expanded form of equation (2) developed by Higuchi 
has been shown useful in characterizing the penetration of 
substances through the skin (28) • 
P C D A 
dQ v s 
= -------
dt L 
Where; 
DQ/DT is the steady state rate 
of penetration 
Equation (3) 
( P is the effective partition coefficient of drug between skin barrier and vehicle {P = Cs/Cv, where; Cs is the concentration of 
drug in the skin and cv is the concentration 
of drug in the vehicle. 
cv is the concentration of drug 
dissolved in the vehicle 
Ds is the diffusivity or average permeability 
of the skin barrier 
A is the area of skin to which the 
drug is applied 
L is the effective thickness of the 
skin barrier. 
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Equation 3 all ow s prediction of diffusion rates based 
on the physical , ~ nu chemical properties of the membrane, 
penetrant, and vehicle as described by P, the effective 
partition coefficient, and Ds, the diffusion constant of the 
drug in the ski ~ ba rrier. The partition coefficient has 
been characterized by Higuchi as the most important variable 
in determining diffusion rates, depending en both molecular 
structure and particle size, while Ds varied only slightly 
for substances of similar molecular weight and shape. 
These two terms have been combined to form a 
permeability coefficient, kp, which specifies the 
permeability of a membrane to a given penetrant {29). 
PD 
s 
kp = 
L 
Equation (4) 
While equation three has been found usef ul in 
predicting steady-state diffusion rates it has been shown to 
12 
have several shortccmings; the most serious involve the 
partition coefficient. This factor is generally determined 
in systems other 
oil/water being 
than stratum corneum/vehicle, with olive 
typical of the systems most commonly used. 
While there is evidence to show simple relationships between 
partition 
there are 
coefficients in one system compared to another, 
numerous deviations (30). Further, in defining 
the partition coefficient as Cs/Cv, formulation variables 
are not considered. Higuchi (28) has suggested that Cv be 
replaced by a thermodynamic activity term which incorporates 
properties of the vehicle into the partition coefficient and 
thus equation 3. The thermodynamic activity is defined as 
the concentration in the vehicle divided by the solubility 
in the vehicle (Cv/Cs) and is a more accurate indicator of 
the driving force for diffusion. For a given system the 
thermodynamic activity of a penetrant in a vehicle and 
release rate from the vehicle increase up to saturation. 
There are a number of other limitations to the application 
of equation 3, for example, it applies only to steady-state 
diffusion rates in systems where the rate-limiting step is 
diffusion across the skin, and only for penetrants in low 
concentrations , in vehicle, since high concentrations cause 
deviations from Fick's Law. 
Correlation of calculated diffusion rates vith 
experimental 
Calculated 
results may be poor for several reasons. 
rates depend on experiments in which the 
parameters are generally controlled, i.e. (1) the following 
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concentration of penetrant in the vehicle remains constant, 
(2) sink conditions exist within the membrane, and (3) the 
characteristics of the vehicle remain constant (29). It is 
obvious that this type of control does not exist in the 
clinical setting. In addition, equation 3 does not account 
for the effect the vehicle or penetrant may have on the 
skin. The vehicle may cause hydration of the skin altering 
permeability, moreover, the penetrant may modify the barrier 
properties of the membrane or be bound within the skin, 
affecting the rate of penetration. 
In spite of these limitations, the use of equation 3 
and its derivatives is important in providing rough 
estimates of steady-state diffusion rates. 
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F. Previous Work ( 
Salicylic acid has been used by early workers 
attempting to characterize the mechanisms of percutaneous 
absorption and more recently by those interested in the 
effects of vehicles and/or additives on the rate of 
penetration. Barr (31) and Idson (32) have published 
excellent reviews of percutaneous absorption which refer to 
much of the earlier vork in which salicylic acid was 
included. Notable among these early works are those of 
Kimura (33) and Nogami (34) who were among the first to 
consider the effect of the vehicle on the rate and extent of 
absorption of salicylic acid. 
Much of the work dealing specifically with salicylic 
acid or salicylates has been published within the past 
twenty years and can be conveniently divided into in vif£Q 
and in vivo studies. 
1. In Vitro 
~
Because of the limited application of in vit£Q results 
to in vivo situationsr the number of significant studies is 
small. In vitro studies are essentially limited to 
determing penetrant release from ointment bases without 
characterizing absorption. Such systems for examing drug 
release typically rely on a "dialysis" or "diffusion" cell 
in which donor and receptor phases are separated by a 
15 
membrane, usually cellophane or silicone rubber, although 
excised human skin has been used. 
Howze and Billups (35) used a dialysis cell with a 
cellophane membrane to examine salicylic acid release from 
eight ointment bases. Release was determined by measuring 
salicylic acid concentration in the aqueous donor phase at 
various time intervals. Ranked from most rapid release to 
slowest, Howze and Billups reported oil/water emulsions 
greatest, followed by water/oil emulsions, oleaginous 
systems, and finally aqueous systems. A similar report by 
Billups and Patel (36) corroborate the above pattern using a 
wider variety of individual ointment bases. 
Nakano and Patel (37) studied the in vitro release of 
salicylic acid from ointments using a dialysis system with a 
silicone rubber membrane. The release rate reported was 
essentially the same as Howze and Billups (35) with the 
addition of polyethylene glycol ointment which showed the 
slowest release rate. Higuchi and Lach (38) have postulated 
the formation of a complex between salicylic acid and 
polyethylene glycol vhich may slow diffusion through the 
membrane. 
In addition Nakano and Patel (37) examined the uptake 
of salicylic acid from ointment bases by reversing the donor 
and receptor phase and measuring the rate of uptake into the 
aqueous phase. The results show that in the absence of 
specific interactions between drug and base, the ointment 
that takes up salicylic acid the fastest, releases it the 
16 
fastest. 
~oisture and the extent of hydration are known to 
affect percutaneous absorption considerably. Water, alcohol 
and dimethylsulfoxide were each incorporated into four 
ointment bases, white petrolatum, cottonseed oil base, 
water-in-oil emulsion and an oil-in-water base. All three 
liquids enhanced release from white petrolatum and the 
water-in-oil base but inhibited diffusion from both the 
oil-in-water and cottonseed oil formulas. While no general 
explanations are possible, the results are important in 
showing that diffusion from ointment bases is influenced 
greatly by the inclusion of liquids. 
Bot tare il al. (4 0) studied the influence of drug 
concentration on the in vitrQ release of salicylic acid from 
ointment bases. In addition to reconfirming the release 
rate patterns established by previous vorkers, they applied 
the equation, developed by Kozumi and Higuchi (41) for those 
cases where diffusion through the vehicle is rate-limiting. 
Equation (5) 
Where; 
dQ/dt is the rate of absorption 
A is the concenetration of drug per unit 
volume. 
D is the diffusion coefficient constant 
Cs is the drug solubility in the vehicle 
( 
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t is time 
The results indicate that release proceeds linearly only 
within the solubility range of drug within a given vehicle. 
Following saturation, increases in drug concentration show a 
smaller effect on release rates. Whether the change in 
release rates demonstrated is strictly due to saturation of 
the drug in a vehicle is questionable since the diffusion 
coefficient (D) has been shown to be concentration dependent 
in some cases (40). However, the correlation between 
release rates and concentration within a specific 
concentration range demonstrates the usefulness of this 
equation as a predictor of drug release rates. 
Several workers have examined the effect of ointment 
bases on the release of salicylic acid in vivo. Early 
studies on the effects of various oily vehichles on the 
absorption of salicylic acid showed absorption from lard and 
lanolin but little from petrolatum (33). Strakosch, using 
emulsion bases, , reported little effect of the vehicle on the 
absorption of salicylic acid (42). Several workers have 
since examined the effect of ointment bases on the release 
of salicylic acid in vivo and shown a substantial effect due 
to the vehicle. 
Stolar, Barr, and Rossi (43) have published work 
involving 
which the 
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the percutaneous absorption of salicylic acid in 
primary aim was to develop a standardized 
procedure for determining absorption through intact skin. 
Ointments were applied to intact shaved skin of rabbits by 
means of a bandage specifically designed to standardize the 
area of application. Absorption was characterized by 
determining the salicylic acid concentration in plasma at 
one hour intervais for a period of eight hours. The extent 
of absorption from each of four physical types of ointment 
bases, hydrophilic ointment, hydrophilic petrolatum, 
petrolatum, and polyethylene glycol ointment was determined. 
Since hydrophilic ointment contains 37% water, the 
thermodynamic activity of salicylic acid in this vehicle 
would be expected to be high. On the basis of solubility 
and the anhydrous nature of both hydrophilic petrolatum and 
petrolatum the thermodynamic activity of salicylic acid 
would predictably be lower. In polyethylene glycol the 
activity is lowest because of possible complex formation 
(38) • 
The results shown by Stolar ~i ~ are in accord with 
predictions which can be made from equation 3 as modified by 
Higuchi (28). Colazzi (44) and Stelzer e t ~.!.:.. (45) have 
also examined the effects of vehicle a nd shown similar 
patterns to those obtained by Stolar et al~i Shelmire (46) 
working with 
reported rates 
thermodynamic 
water containing emulsions of salicylic acid , 
of penetration to be rapid, based on the 
activity of salicylic acid in aqueous 
19 
vehicles. 
~ashitake, et al. (47) compared absorption of salicylic 
acid from a series of oily vehicles by determing drug loss 
from the vehicle. The rate of loss was found to be directly 
proportional to the oil partition coefficient of the drug. 
Studies on the absorption of salicylic acid from 
polyethylene glycol 400 and four other hydrophilic vehicles 
showed that the partition coefficient of the drug between 
the vehicle and benzene correlated well with the rate of 
absorption. 
The effect of hydration on the absorption of salicylic 
acid has been studied by Wurster and Kraemer (48). To avoid 
the influence of diffusion through vehicles, pure penetrants 
were used. Three liquid salicylate compounds were tested; 
ethyl salicylate, methyl salicylate and ethyleneglycol 
salicylate. Absorption was measured as a function of total 
salicylate recovered in urine. A hydrated condition was 
created by occlusion with a specially designed "absorption 
cell"; the anhydrous state was produced by incorporating a 
dessicant into the cell. A significant increase in the rate 
of absorption was caused by the hydrous condition of the 
skin. The increase was greatest for the most water soluble 
salicylate (ethyleneglycol salicylate). For the three 
esters studied, the extent of increase in absorption was 
shown to be inversely proportional to the oil/water 
partition coefficient and directly proportional to its 
aqueous solubility. 
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Wurster and Kraemer (48) also studied the effect of 
defatting the skin on the absorption of salicylic acid. The 
skin was defatted by immersing the subject's forearm in 
ethyl ether for a one minute period. Methyl salicylate was 
applied as previously described and urinary salicylate 
levels were determined. The same procedure was carried out 
on skin not treated with ether. Following the defatting 
procedure the absorption of methyl salicylate was 27% less 
than that observed in subjects vho had not been treated with 
ether. The authors suggest that the difference in 
absorption is primarily due to the destruction of the lipid 
pathways through which the drug normally diffuses. In 
addition, the ether extraction may have directly removed 
water from the skin or alter the lipid membrane to create a 
partially dehydrated condition. The resulting anhydrous 
condition of the defatted skin would result in a more 
effective barrier to penetration than normal or hydrous 
skin. 
Higuchi ( 28) has stated that the driving force for 
percutaneous diffusion is the thermodynamic activity or 
activity coefficient. He has also shown that for weakly 
acidic drugs, such as salicylic acid, activity is inversely 
proportional to 10~". Arita et al. (49) and Marcus g1 al. 
(50) have examined the effects of pH on the rate and extent 
of absorption of salicylic acid. 
Arita and colleagues, using the intact skin of guinea 
pigs, determined the absorption of salicylic acid as the 
...... 
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percent of drug lost from Sorenson's phosphate buffer over a 
six hour time period. Varying the pH from an initial value 
of 2 to 5 caused a decrease in the amount of salicylic acid 
absorbed from six percent at pH 2 to essentially zero at a 
pH of 5. As the pH changed from 2 to 5, the authors noted a 
decrease in the oil /water partition coefficient, pointing 
out the importance of this term in percutaneous absorption. 
Marcus et al. (50) , examined the effect of pH on the 
absorption of salicylic acid from hydrophilic ointment. 
Absorption was studied by measuring salicylate blood levels 
in rabbits according to the method of Stolar et al. (43). 
At low pH (2.97) absorption was significantly higher than at 
intermediate levels, i.e., 4.48, 6.80, and 9.23. These 
results would be predictable from the work of Higuchi and 
Lach (38) • Marcus et al. (50) noted that dissolution is 
often the rate limiting step in absorption from the 
gastrointestinal tract and may be a factor in this case. 
The effect of additives on the absorption of drugs from 
various vehicles has long been of interest. Marcus et ~l~ 
(50), Stelzer et ~ (45) and Shen et al. (51) have studied 
the effects of formulation additives on the percutaneous 
absorption of salicylic acid. 
Stelzer et al. (45) examined the influence of dimethyl 
sulfoxide on the absorption of salicylic acid in each of 
four ointment bases. Absorption was determined by the 
method of Stolar et al. (43). The addition of 15% DMSO to 
these bases and to a fourth base, polyoxyethylene stea~yl 
( 
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ether gel, produced mixed results. The absorption of 
salicylic acid from hydrophilic ointment and hydrophilic 
petrolatum was significantly increased. Little effect was 
shown on the 
polyethylene 
absorption characteristics of 
glycol ointment or the ether gel. 
either 
The authors 
report that the 103 salicylic acid vas completly solubilized 
by the DMSO in all four ointment systems. It has been 
previously shown that organic solvents penetrate the skin 
and enhance the _percutaneous absorption of drugs by 
solubilizing the lipoidal materials of the cell walls. 
Stelzer et al~ (45) attribute the increas e · ~ absorption of 
salicylic acid to the ability of DMS O t o solubilize 
salicylic acid and then serve as a penetrant carrier. It 
should be pointed out however. that the precise mechanism by 
which DMSO enhances permeability is ess ~nti a lly unknown 
(43). In the same study, DMSO had little effect on the 
absorption of the glycol ointment bases. The possibility of 
complex formation between glycols and salicylic acid has 
previously been reported (38) • It is also known that drugs 
held within vehicles by such complexes exhibit low 
thermodynamic activites. The negligible effects of DMSO on 
absorption from the glyccl bases in this study suggest that 
the penetrant has little effect on the complex and as such 
does not significantly improve the thermodynamic activity of 
salicylic acid in these vehicles. 
Marcus et al. (50) also showed an increase in the 
absorption of salicylic acid from hydrophylic ointment over 
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a pH range from 2.97 to 10.78 following the addition of 
DMSO. However, its influence on the rate of absorption and 
on peak levels was less pronounced at the higher pH values. 
The authors suggest that this finding indicates that the 
effect of DMSO on absorption is a function of its ability to 
solubilize salicylic acid within the ointment base rather 
than any direct effect as a penetrant or carrier. 
Shen and co-workers have recently examined the effects 
of non-ionic surfactants on percutaneous absorption of 
salicylic acid in the presence of DMSO (51). Ten percent 
salicylic acid was incorporated along with 10% DMSO into 
white petrolatum containing a variety of surfactants. The 
method for studying absorption was based on the work of 
Stolar et al. (43). Results indicate that a wide range of 
non-ionic surfactants improved absorption of salicylic acid 
and sodium salicylate. The mechanism by which surfactants 
enhance absorption is unknown but a 
dimethylsulf oxide-drug-surfactant complex is suggested. 
Shen et al. (51) also suggest that the formation of such a 
ccmplex results in an increased activity coefficient, 
accounting for an increase in absorption as predicted by 
Higuchi (28). 
The effects of percutaneous absorption through damaged 
skin have been discussed previously. Stoughton (6), Katz 
(7), and Wurster (52) have published excellent reviews on 
percutaneous absorption which include discussion on the 
effects of removal of the barrier layer of the skin. 
24 
Washitake ~ al. (53) have examined the effect of 
repetative stripping of the stratum corneum on the 
percutaneous absorption of salicylic acid. Absorption was 
calculated as the amount of salicylic acid remaining in the 
test vehicle over a six hour period. The results showed a 
significant increase in the amount of drug absorbed; 
stripped skin exhibited a ten-fold increase compared to 
intact skin. The lag time required to reach steady state 
diffusion through intac~ skin was not determined. 
In what may be considered the first clinical 
pharmacokinetic study involving salicylic acidr Taylor and 
Halprin (54) examined the absorption of salicylic acid in 
four patients suffering from psoriasis. Salicylic acid was 
applied in the form of a gel containing 6 percent drug in a 
base containing 60% propylene glycol and 19.43 alcohol. The 
gel vas applied in a fixed amount to the entire body surface 
of the patients and the treated areas occluded with plastic 
wrap. 
hours. 
The dressing was left intact for a period of ten 
The procedure was repeated daily for five days. 
Serum samples . were collected at six hour intervals for the 
entire test period. When applied under occlusion, salicylic 
acid was rapidly absorbed from the glycol and alcohol base, 
60% of the applied drug was absorbed. Serum salicylic acid 
levels did not exceed 5 mg., well below the lower limit of 
what is considered a toxic level (30 mg ) (55). 
III. "ETHOD 
A. Materials 
1. Chemicals 
Salicylic Acid, A.c.s. (lot # 743715) 1 
Sodium Tungstate A.C.s., (lot # 744002 & 755089) 1 
Sodium Hydroxide A. c. s., (lot # 75264 2) 1 
Ferric Nitrate, A.c.s., (lot# 751140)1 
Mercuric Chloride, A.c.s., (lot# 752538) 1 
Urea, A.c.s., (lot 751363) 1 
Hydrophilic Ointment, U. s. P., (lot # Y4663KO 1) 2 
Hydrochloric Acid, A.C. s., (lot # 1090 216R60) 3 
Sulfuric Acid, A.c.s .. , (lot# E 911015)3 
Polyethylen Glycol 400, U .. s. P., (lot Y4023J23) • 
Liquamin Sodium "10", Sodium Heparin Injection, U.S.P. 
(lot# 6853575811)5 
1. Fischer Scientific company, Fairlawn, Nev Jersey 
2. Armand Drug and Chemical Co., Irvington New Jersey 
3,. B & A, Allied Chemical Specialty Divisions, 
Morristown, ~ew Jersey 
• Ruger Chemical co., Irvington, New Jersey 
s. Organon Incorporated, West Orange, New Jersey 
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B. Reagents 
Tungstic Acid Reagent was prepared by mixing together 
ten percent aqueous sodium tungstate solution 
(10ml.) and 1/12N sulfuric acid (80ml.). 
Trinder's Reagent was prepared by dissolving, with heat, 
forty grams of mercuric chloride in approximately 700 ml. of 
distilled water. Upon cooling, 120 ml. of 1N HCl and forty 
grams of ferric nitrate were added, and the solution brought 
to one liter with distilled water. (The solution, when 
stored in a refrigerator, is reported stable for several 
months.) 
C. Equipment and Supplies 
Fluorometer, Turner Model 111, G.K. Turner Associates, 
Palo Alto, California 
Spectrophotometer, Perkin-Elmer, Model 200, Coleman 
Instruments Division, Oak Brook, Illinois 
Ointment Kill, Hammonia Model, Josef Deckelmann, 
Aschaffenburg, West Germany 
Butterfly-21, Intermittent Infusion Set, Abbott 
Laboratories, North Chicago, Illinois 
Plastipak Disposable 3 ml. Syringes, Becton-Dickinson 
and Company, Rutherford, New Jersey 
Sterile, Disposable Needles, 25G, 5/8", Becton-Dickinson and 
company, Rutherfood, New Jersey 
vacutainer, Evacuated glass tubes, Beckton-Dickinson 
and Company, Rutherford, New Jersey 
Rabbits, New Zeala.nd Females, five to six pounds, 
Gloucester Rabbitry, Chepachet, Rhode Island 
Glassware and common laboratory equipment as available 
in the college of Pharmacy 
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D. Procedures 
1. Ointment Preparation 
Hydrophilic Ointment U.S.P., obtained commercially, was 
milled, using a Hammonia Ointment Mill, to improve 
consistency and ease of application. 
a. 10% Salicylic Acid Ointment 
To provide 
incorporation 
A.c.s., fine 
a more uniform particle size range for 
into the ointment base, salicylic acid, 
crystal, was passed through an 80-mesh seive. 
Six grams of the salicylic acid were then incorporated into 
54 grams of hydrophylic ointment using the pharmaceutical 
technique of geometric dilution. No levigating or 
preservative agents were incorporated into the ointment 
base. Hard rubber spatulas vere used throughout the 
procedure to avoid any possible contact between iron and 
salicylic acid which produces the iron salicylate complex 
manifest by a purple coloration of the ointment. 
( 
\ 
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b. 103 Urea, 103 Salicylic Acid Ointment 
Six grams of urea, passed through an 80 mesh seive, were 
incorporated into 24 grams of previously milled hydrophilic 
ointment 
technique, 
into 24 
by the method of geometric dilution. By the same 
six grams of salicylic acid were incorporated 
grams of hydrophylic ointment. The two ointment 
mixtures were combined, geometrically, to produce a test 
ointment containing 103 urea and 10% salicylic acid (w/w). 
2. Rabbit Preparation 
Female New Zealand rabbits, age approximately five 
months, weighing two to three kilograms, were housed in 
humidity and temperature controlled quarters and maintained 
on a diet of Charles River Rabbit Chow and water ~~ !iQ~ 
The animals were observed for a period of one week following 
delivery; if no signs of ill health were detected the 
rabbits were released for experiments. 
Clay and . Nelson (56) have suggested that the dermal 
permeability of drugs may be altered by stress; therefore, 
all rabbits to- be used for experimentation were put through 
an established routine. For several days prior to 
application of a test ointment, each rabbit was placed in a 
restraining cage for increasing periods of time, in order to 
condition the animal to the restraining box and relieve 
stress associated with this test condition. Two to three 
( 
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hours prior to application of a test ointment, the hair on 
the ventral side of the animal from the forelegs to the 
hindlegs vas removed with animal clippers, taking care not 
to cut or otherwise visibly damage the skin. 
Immediately prior to application of ointment, an 
intermittent infusion set, 21G, 5/8" needle, was inserted 
into the main ear artery. A blood sample was collected to 
serve as a zero time determination and the infusion line was 
cleared with a dilute {100 units/ml.) heparin solution to 
prevent clot formation. 
An accurately weighed sample of ointment vas spread over 
a standard, rectangular, (7 cm. x 13 cm.) template (Similar 
to the control technique reported by Stolar et al~ (43)). 
The template was centered on the adhesive surface of a strip 
of adhesive tape; the assembly was carefully inverted and 
applied to the previously shaved area of the animal. The 
rabbit was then placed in a restraining box for the duration 
of the experiment. Water was provided ad lib.i food was 
given or withheld depending on the test conditions for the 
particular study. Blood samples were drawn at specified 
intervals for twenty four hours following initial 
application of· the test ointment. All blood samples were 
allowed to clot, centrifuged at approximately 2000 RPM for 
ten minutes, and then at least one ml. of serum was drawn 
off and stored under refrigeration until analysis. 
Since the proper determination of the pharmacokinetics 
of a drug usually involves the collection of blood samples 
( 
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for a period of four to five half-lives following its 
administration, the characterization of the pharmacokinetics 
of percutaneously absorbed salicylic acid would likely 
require a sampling time of twenty to twenty four hours. The 
collection method used in this investigation was a 
modification of that described in the literature. Instead 
of hourly puncture of the ear vein, the previously described 
infusion set was placed in the ear artery and remained in 
place throughout the sampling period. Thus, blood could be 
drawn at any time; the insertion of only one needle 
considerably reduced the possibilities of infection or 
damage to the artery. 
The catheter was kept filled with dilute heparin 
solution between sample collections to prevent obstructions 
from forming. However, obstruction of the catheter 
occasionally occured, particularly during the last six or 
eight hours of an experiment, and was generally due to the 
collapse of the artery around the needle. In some cases 
this was remedied by simply flushing the catheter with 
heparin, or gently warming the ear with a sunlamp. When in 
a few instances the obstruction persisted, the other ear was 
catheterized or- the experiment was terminated. 
Collapse of an artery or damage to t he vessel wall (e.g. 
often made it impossible to use a test animal for 
one experiment, even after a three or four week 
period. Permanent catheterization of the carotid 
scarring) 
more than 
recovery 
artery may provide a more reliable method of sample 
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collection during the course of an experiment; it may also 
offer a method by which animals could be used for more than 
a single experiment. 
3. Human Preparation 
A detailed report of the proposed project, its 
objectives, methods, and potential hazards was submitted to 
both a University Humans Studies Committee and an 
Institutional Review Board for approval (Appendix). 
Following the guidelines established by these committees, 
volunteers were asked to refrain from taking any aspirin or 
aspirin-containing products for one week, and all drugs, 
including alcohol, for 48 hours preceding an experiment. 
Prior to application of a test vehicle, an intermittent 
infusion set, 25G, 5/8" needle was inserted into a vein on 
the back of the subject's hand by a Registered Nurse and a 
blood sample drawn. The infusion line was then cleared with 
a dilute (100 unit/ml.) heparin solution to prevent clot 
formation between sampling times. The appropriate test 
vehicle was then applied to the subjects forearm, for the 
prescribed len~th of time, after which the skin surface was 
washed with warm water and soap 
Two vehicles were used for human experiments; 
polyethylene glycol 400 and water, and 10% salicylic acid in 
hydrophylic ointment. Because one system is a liquid while 
the other a solid, it was necessary to have different 
( 
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methods of application. 
Fifteen 
placed in 
maintained 
liters of the test solution (PEG400:vater) were 
a ten gallon glass tank, constantly stirred and 
at a temperature of 37 degrees. Each subject 
immersed his hand, forearm and distal portion of the upper 
arm in the solution for a period of two hours. For the 
solid system, ointment was applied to the subject's forearm 
and spread evenly over the entire skin surface. The forearm 
was then occluded with plastic film and the ointment allowed 
to remain in place for a period of two hours. The second 
test condition was a modification of the first in which the 
subject shaved the hair off the forearm the night before the 
test. Immediately prior to application of the ointment the 
skin of the volunteer's forearm was "stripped" with adhesive 
tape five times. This process consisted of taping the 
forearm from wrist to elbow and then removing the tape along 
the entire forearm. The test conditions in this case 
required application of the ointment for three hours. 
E. Methodology 
1. Fluorometric 
The primary assay used was the spectrofluorometric 
method developed by Saltzman (57). The method makes use of 
the fluorescence of the salicylate ion on exposure to 
ultraviolet light. 
< 
34 
Nine and one-half ml. of tungstic acid reagent was added 
to 0.5 ml. of serum; the solution was shaken and allowed to 
stand at least ten minutes. The mixture was then filtered 
through medium retentive filter paper and the filtrate 
collected. Five ml. of filtrate were pipetted into a test 
tube and 7 ml. of 10N NaOH added. The solution was mixed, a 
portion transferred to a cuvette, and the fluorescence 
determined within thirty minutes in a Turner Fluorometer 
fitted with a primary filter (7-60) and secondary filters 
( 110-827 and 110-823) • 
A standard reference curve was produced by adding 0.5 
ml. of varying concentrations of salicylic acid to 4.5 ml. 
tungstic acid reagent. Seven ml. of 10N NaOH was added, the 
solution was mixed, and the fluorescence determined within 
thirty minutes. A linear Beer's plot was obtained over the 
concentration range of 0.5 mg% to 20 mg% (rZ=0.99). 
In this procedure tungstic acid reagent serves to 
precipitate serum proteins and separate salicylic acid 
present. sodium hydroxide serves a dual purpose, the first 
is to hydrolyze all salicylate metabolites present to 
salicylic acid. In addition, Saltzman (57} has shown that 
an alkaline condition will increase the fluorescence of 
salicylates; maximum fluorescence was produced using 10N 
NaOH. 
( 
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2. Spectrophotometric 
The secondary assay for the determination of salicylic 
acid in blood relies on the purple color given by a 
salicylate-ferric ion complex. The procedure used is that 
developed by Trinder (58) , as modified by Biber and Rhodes 
(59) • 
Two ml. of serum was pipetted into a 10 ml. volumetric 
flask. Five ml. of Trinder's Reagent was then added. The 
pH was adjusted to 1.5 with 0.3N NaOH and the solution then 
brought to vol '' -· 2 with distilled water. A portion of the 
solution was transferred to a quartz cuvette and the 
absorbance determined at a wavelength of 540 nm., using a 
model 200 Perkin-Elmer spectrophotometer. 
The calibrat _on c urve produced a Beer's plot linear over 
a salicylic acid concentration range of 5mg% to 100 mg~ (rZ 
=0.99). 
In this procedure, mercuric chloride and hydrochloric 
acid are used to precipitate plasma proteins, ferric nitrate 
to generate the salicylic acid-ferric ion complex and the 
purple color on which the colorimetric analysis is based. 
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IV. RESULTS AND DISCUSSION 
A. Animal Pharmacokinetics 
1. Elimination Rate Constants 
Elimination rate constants for salicylic acid were 
calculated for each treatment by each of tvo methods. 
First, when the common logarithm of serum salicylic acid 
concentration was plotted versus time, the slope of the 
terminal 
constant, 
portion 
ke. A 
of the curve yielded the e li ~ ia t ion rate 
representative plot of the log 
concentration versus time plot is shown in Figure 1. 
The second method for determining salicylic acid 
elimination rate made use of a nonlinear an& i ysi s. This 
method involved a computerized iterative technique of 
fitting blood level data using a nonlinear least squares 
regression program. The least squares estimates of the 
kinetic parameters, and the standard deviations and 
confidence intervals of the parameters were all calculated. 
The elimination rate constants as calculated by both 
methods are shown in Table 1. Statistical analysis using 
the student's t test at the 0.01 confidence level indicated 
there was no significant 
constants when calculated 
difference in elimination rate 
by either method. Further, no 
significant differences were found to exist in elimination 
rate constants in animals treated with SA (10% salicylic 
( 
( 
15 
12 
~ 
t!) 
::;;:: 
z 
0 9 ...... 
l-
ct: 
= ~
::z:: 
w 
L.) 
= 0 
L.) 
<C 6 V) 
<C 
:E 
V) 
5 
c._ 
3 
4 12 
HOURS 
15 20 
Figure 1 - Salicylic Acid Concentration In The R~bbit 
Following the Topical Application Of 103 
Salicylic Acid Ointment 
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TREATMENT 
SA 
8 Hours 
SA 
4 Hours 
SAU 
8 Hours 
TABLE I. 
Elimination Rate Constants 
For Salicylic Acid 
Calculated By Two Standard Methods 
Elimination Rate Constant 
(Hr-1) 
(Mean ~ s.d.) 
Method 
ELIMINATION PLOT NO NL IN 
0.409 + 0.27 0.289 + 0.07 
-
0.449 + 0.25 0.496 + 0.14 
0.272 + 0.02 0.269 + 0.07 
-
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acid in hydrophilic ointment) for eight hours versus those 
treated with SA for four hours or those treated with SAO 
(103 salicylic acid and 10% urea in hydrophylic ointment) 
for eight hours. No differences in elimination rate 
constant were expected between treatments since the 
metabolism and excretion of salicylic acid is a function of 
the serum salicylic acid concentrations and would be 
expected to be independent of the type of ointment applied. 
2. Half Life 
Half lives for each treatment were calculated from the 
elimination rate constants determined by plotting the l og 
salicylic acid concentration versus time and obtaining the 
slope of the elimination phase portion of the curve. Since 
salicylic acid has been shown (23) to follo w first order 
kinetics at low doses, half-life was calculated according to 
equation (6). 
T1/2 = 0.693/ke 
Equation (6) 
Calculated halr-lives are presented in Table 2. No 
statistical differences were shown between a n y treatments. 
TREATMENT 
SA 
8 Hours 
SA 
( 4 Hours 
SAU 
8 Hours 
TABLE II. 
~ean Salicylic Acid Half-Lives 
HALF-LIFE (HOURS) 
(mean ! s. d.) 
1.93 + 1. 00 
1.83 + 1. 04 
2.01 + 0.08 
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3. Absorption Rate Constants 
The ilagne r- Ne ls on method is commonly used to 
characterize the absorption process. This technique 
based on the one compartment open model, and can be used 
obtain data from which the order of absorption and 
appropriate rate constant can be calculated. The 
Wagner-Nelson equation is: 
At/V = Ct + KJcpdt 
Equation (7) 
Where; 
At/V is the amount of drug in the body at time t, 
divided by the volume of distribution V, 
Ct represents the concentration of drug in the blood 
at time T, and the integral Kf cdt represents the 
cumulative amount of drug eliminated to time t. 
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is 
to 
the 
If the plot of the logarithm of the change in At/V 
(dAt/V) versus time is linear, the absorption process can be 
characterized as first order and an absorption rate constant 
determined. 
The plots of the log of absorption rate versus time 
proved linear for all treatments; i.e., the absorption of 
topically applied salicylic acid can be characterized as a 
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first order process. The slope of the line generated from 
data gathered from animals treated with SA for four hours, 
SA for eight hours, or SAU for eight hours yielded apparent 
first order absorption rate constants of 0.516 Hr-1, 0.340 
Hr-1, and 0.306 Hr-1, respectively. Absorption rate 
constants for each treatment are shown in Table 3 and a 
dAt/V versus time plot is given in Figure 2. 
Data obtained from the Wagner-Nelson equation may be 
treated by a second method to calculate ka. At t infinity, 
Ct is equal to zero and the asymptotic value of the function 
is described as A/V = kjcpdt, where, A/V represents the 
total amount of drug absorbed divided by the volume. By 
expressing the amount of drug absorbed at time t as a 
percentage of the total amount absorbed (A/V} and 
subtracting from 100, the percent remaining to be absorbed 
was calculated. It is critical that an accurate value of 
A/V be used • Wagner bas reviewed this method and discusses 
the causes of error in estimating A/V and the effect this 
has on calculated ab~orption rate constants. Plotting the 
log of the percent remaining to be absorbed versus time 
yields an absorption plot from which ka can be calculated by 
determining the slope of the line, Fig ure 3. Absorption 
rate constants calculated using this technique appear in 
Table 3. Statistical analysis using the Student's t test 
showed no significant difference (p = 0.01) in the values of 
ka calculated by either the rate method of Wagner-Nelson or 
the percent remaining technique. The similarity of the 
TREATMENT 
SA 
8 Hours 
( SA 
4 Hours 
SAU 
8 Hours 
( 
TABLE III. 
Salicylic Acid 
Rate Constants 
Calculated By Three Standard Methods 
ka (Hours- 1 ) 
(mean+ s.d.) 
WAGNER-NELSON PERCENT REMAINING 
0.340 + 0.28 0.280 + 0. 11 
- -
0.516 + 0.01 0.603 + 0.03 
- -
0.306 + 0.01 0.309 + 0. 12 
- -
NO NL IN 
0.249 -+ 0.07 
0.492 + 0. 14 
-
0.271 + 0.07 
-
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Figure 2 - Absorption Rate Of Salicylic Acid 
Calculated By The Wagner-Nelson Method . 
(Rabbit D) 
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absorption rate constants was evidence that the calculated 
value of A/V was accurate. 
Since the absorption process was characterized as first 
order, fitting the one compartment open model, the data was 
treated by the method of nonlinear least squares regression 
(NONLIN), using the one compartment open model with a first 
order absorption rate constant, ka. Initial estimates of ka 
and ke were obtained from the Wagner-Nelson and log 
concentration versus time plots respectively. The NONLIN 
program uses an iterative process to "fit" a one compartment 
open model, with first order absorption to the blood level 
data. An example fit is shown in Figure 4. The absorption 
rate constants obtained by the NONLIN fits appear in Table 
3. At the 
difference 
0.01 confidence level there was no significant 
between the values of ka calculated by this 
method and either of the methods previously discussed • . 
Comparison of absorption rate constants obtained from 
animals treated with SA for eight hours with those treated 
with SA 
the 0.01 
for four hours showed no significant difference at 
level. This result was expected since the 
absorption rate depends on the characteristics of the drug, 
its vehicle and the barrier properties of the skin and not 
the lengtn of time of application. 
Comparison of absorption rate constants calculated in 
animals treated with SA ointment for eight hours with those 
treated ~ith SAU ointm~nt for eight hours showe d no 
statistical difference. It appears that the addition of ten 
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percent urea to the "standard" ointment had no eff~ct on the 
rate at which salicylic acid entered the bloodstream. 
However, only a small number of animals were treated with 
the urea-containing ointment. As a result of the small 
numfier of degrees of freedom, the student's t test would 
require a large difference in the values of ka in order to 
show a significant difference between ointments. Comparison 
of the two ointment types among a larger population might 
show significant differences in the rate of absorption. 
However, it seems unlikely that the addition of ten percent 
urea would show any clinically significant increase in the 
absorption of topically applied salicylic acid. 
4. Lag Time 
The lag time may be defined as the time required after 
application for the first order absorption process to to 
begin. Extrapolation of the line generated from the log 
percent remaining versus time curve to the y axis will yield 
the estimated · lag time for each treatment. calculated lag 
times are shown in Table 4. 
Lag times ·calculated from animals treated for eight 
hours with SA ointment and those treated with SAU ointment 
were significantly different at the 0.01 level. Similarly, 
significant differences were shown to exist for animals 
treated with SA ointment for eight hours compared with those 
treated with the same ointmen t for a four hour period. 
( 
TREATMENT 
SA 
8 Hours 
SA 
4 Hours 
SAU 
8 Hours 
TABLE IV. 
Salicylic Acid Absorption Lag Times 
Calculated By Two Standard Methods 
Lag Time (Hours) ~ s.d. 
PERCENT BEMAINING NONLIN 
1.09 + 0. 1 6 0.85 + 0.15 
0.86 + 0 . 06 0.87 + 0.02 
0.99 + 0.13 0.79 + 0.08 
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Differences in 
likely caused 
lag 
by 
50 
times were unexpected and were most 
inadequate sampling during the earliest 
stages of the absorption process; the earliest blood samples 
were not drawn until after the end of the calculated lag 
time. Lag times are generally useful for cases in which 
systemic absorption is desired, the significance in topical 
systems is of less general importance. 
5. Bioavailability 
One of the most important parameters for determining 
relative bioavailability is the area under the blood 
concentration time curve. Areas under the curve (AUC) can 
be calculated by the trapezoidal rule. This value is 
proportional to the amount of drug absorbed. A Fortran 
computer program was written to calculate the AUC for each 
treatment; values of AUC are given in Table 5. 
The relative extent of absorption can be determined by 
comparison of AUC of two products. The cumulative areas 
under the curve obtained from animals treated with SA for 
four hours and those treated with SAO ointment for eight 
hours were each compared to the SA ointment (without urea) 
applied for eight hours. No significant difference (p=0.01) 
could be shown between either treatment and the "standard" 
ointment. 
Serum salicylic acid concentrations for animals treated 
for eight hours generally did not peak fo r five to six hours 
Treatment 
SA 
8 Hours 
SA 
4 Hours 
SAU 
8 Hours 
Table v. 
Areas Under The curve For 
Topically Applied Salicylic Acid 
In The Rabbit 
AOC 
(mg. ml.-t Hours) 
141.35 + 39.54 
~ 
28. 95 + 66.52 
154.30 + 10.04 
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application of the ointment, in agreement with 
reports (43,44) • Those treated for only four 
essentially still in the absorptive phase when 
the ointment was removed, therefore, less salicylic acid was 
available for absorption. The wide variation in AUC 
calculated from animals treated for eight hours and the 
small number of animals treated for four hours most likely 
made the 
AUC's for 
the curve 
paired 
these 
between 
t statistic insensitive to differences in 
tvo groups. Comparison of the area under 
larger populations may be necessary to 
show any significant difference between these treatments. 
Although no significant difference in areas under the 
curve could be demonstrated in animals treated with SAU 
ointment compared with those treated with salicylic acid 
alone, it is not possible to conclude that there is no 
effect of ointment on AUC. Because blood level data were 
obtained from only two animals treated with urea, the test 
statistic must necessarily be very large in order to show 
significance. Further work using more animals would be 
necessary to reach any conclusion regarding the effect of 
urea on the absorption of salicylic acid measured as the 
area under the blood level time curve. 
6. Feeding Studies 
In contrast to previous studies (43,44) in which 
animals were fasted throughout an experiment (i.e. for the 
( 
period 
blood 
of ointment 
sampling) a 
53 
application and the entire period of 
series of experiments was completed in 
which animals were fed during the sample collection period. 
Fifteen hours following the application of SA ointment, 
four animals were fed approximately 30 grams of Charles 
River Rabbit Chow. A representative salicylic acid 
concentration time profile is shown in Figure 5. A second 
peak was observed in each profile within two or three hours 
following the feeding of the test animal. Since the second 
peak occurs approximately eight to ten hours after the 
removal of the test ointment the peaks cannot be attributed 
to additional absorption of salicylic acid through the skin. 
The presence of the second peak can probably be 
attributed to biliary recycling. Biliary recycling can be 
defined as the process by which drug is secreted into the 
bile and then passed into the small intestine. The drug can 
then be reabsorbed from the intestinal lumen into the 
systemic circulation. Rischel (60) has stated that 
recycling of drugs excreted into bile in unchanged form and 
for metabolites is possible, if they are either absorbed or 
modified by the gut flora, particularly after splitting of 
conjugates. The form of drug which is excreted into the 
bile also affects biliary recycling, drugs which form 
glucuronides have been shown to undergo recycling since t he 
glucuronide can be readily cleaved to form the free drug in 
the bile. Salicylic acid is metabolized by the liver and 
54 
its metabolites, SAG, SPG, GA, and SU, are found in the bile 
( (25) • If the unchanged drug and the glucuronides, SAG and 
SPG account for the majority of the drug in the bile of 
rabbits, as in man, it is likely that biliary recycling is 
occuring. 
The result of biliary recycling of drugs is commonly 
seen as either a series of "irregularly spaced peaks" in the 
declining portion of a blood concentration time curve or 
simply a prolonged elimination phase. The characteristic 
single second peak shown in Figure 5 can be explained by the 
test conditions imposed in this experiment. The test 
animals were fed only a small quantity of food at a 
determined time, any food not consumed within thirty minutes 
was removed. Food is known to be a stimulus for the ( 
secretion of bile. Protein and fats in particular are known 
to increase bile flow (60). Since the rabbit is known to 
store bile and release it upon stimulation such as food 
(61), it is possible that the stimulus provided by the small 
amount of food caused the release of bile which in turn lead 
to the reabsorption of salicylic acid. 
( 
20 
18 
+ 
16 
4 . 12 16 
P.Ot?.S 
Figure 5 - The Effect of Feeding On 
The PlasQa Salicylic Acid Concentration Ti3e 
Profile Following The Topical Adwinistration 
Of Salicylic A.cid. {?abbit E) 
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B. Human Pharmacokinetics 
1. 3% Salicylic Acid in 40% Polyethylene 
Glycol/Water Solution 
a. Intact Skin 
56 
A mixture of polyethylene glycol 1500 and water was 
chosen as a vehicle for two reasons: first, as a liquid 
systemr it was felt that diffusion through the vehicle would 
not be a rate-limiting step as is the case with some 
ointments, so that absorption rates obtained would more 
accurately reflect the processes of diffusion into the skin; 
secondlyr the polyethylene glycol 400/water mixture provided 
a system in which salicylic acid was sufficiently soluble to 
attain the concentrations required to match those of several 
clinically used products. 
The systemic absorption of salicylic acid applied in 
the PEG/Water vehicle for a period of two hours was minimal. 
Plasma salicylic . acid concentrations was found to be less 
than 1 mg% for each of two experiments. 
The poor systemic absorption may be attributable to the 
formation of a glycol-salicylate complex resulting in a 
molecule too large to easily pass the stratu~ £Qf,!!gQ~~ 
Higuchi (28) has suggested the possibility of a complex 
formation between the higher molecular weight polyethylene 
glycols, e.g., PEG 6000 and salicylic acid. Several • orkers 
( 
( 
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including Colazzi (44) and Stolar (43), have reported low 
serum salicylic acid concentrations when polyethylene glycol 
ointment was used. In addition, Nakano and Patel (37) have 
demonstrated a low release rate of salicylic acid from this 
ointment. Salicylic acid absorption from the vehicle used 
in this investigation had not previiously been reported. 
Although the systemic absoprtion of salicylic acid from 
this vehicle was limited (Figure 6) suggesting the 
possibility of complex formation in the lower weight 
glycols, the keratolytic effect was not. In both 
experiments, extensive keratolysis was observed within 
twenty-four hours of application of the test vehicle. The 
use of polyethylene glycols as vehicles for topically 
applied salicylic acid may prove to be useful in effecting 
keratolytic activity without the dangers of systemic 
absorption. 
2. 10% Salicylic Acid in Hydrophylic Ointment 
a. Intact Skin 
SA ointment' was applied, as previously described, to the 
forearm of four subjects. The skin at the site of 
application was intact, providing a condition of normal 
barrier function. 
The systemic absorption of salicylic acid under these 
conditions was poor. Serum salicylic acid concentrations 
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Figure 6 - Plasma Salicylic Acid Concentration 
In Human Following The Percuta~eous Application 
Of 3% Salicylic Acid In 40~ PEG/WATE~. 
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observed in each subject over an eight hour period were not 
significantly different from the serum concentrations taken 
prior to application of the test vehicle. These 
observations would seem to indicate that the possibility of 
systemic salicylic acid toxicity from the topical 
application of 10% salicylic acid ointment to intact skin is 
remote. 
b. Stripped Skin 
The strai~ corneum on the right forearm of two 
volunteers was disrupted as previously described. This 
technique was used in order to examine the absorption 
kinetics of salicylic acid ointment in a condition 
resembling that of diseased skin. sA ointment was applied 
for a period of three hours, under occlusion, after which 
time the ointment was removed by gently washing the test 
area with warm water and soap. Estimates of the kinetic 
parameters, i.e., ka, ke, half-life, and lag time, derived 
from topically · applied salicylic acid are therefore based on 
data collected from one subject due to difficulties in 
collection of · samples from one of the other subjects. The 
parameters calculated by the methods previously described 
are shown in Table 6. 
The half-life calculated from the slope of the 
elimination phase of the log concentration versus time plot 
was 3.45 hours, in agreement with half-life values reported 
( 
( 
TABLE VI. 
Pharmacokinetic Parameters for Salicylic Acid 
Obtained From The Percutaneous Application Of 
Salicylic Acid In A Human Subject 
PARAMETER VALUE 
Ka 0.189 Hr.-t 
Ke 0.201 Hr.-t 
Half-Life 3.45 Hr. 
Lag Time 1.19 Hr. 
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for salicylic acid after lov dosesr i.e.r when the 
elimination rate has been shown to be an apparent first 
order process. 
Kinetic parameters obtained as previously described were 
used as initial estimates for NONLIN. The computer 
generated parameters are shown in Table 6. The parameters 
obtained from NONLIN are statistically different from those 
obtained by the methods previously described. This is due 
to small number of data points obtained from the human 
subject which could not be properly fitted using the 
computer. 
The absorption and elimination rate constants 
calculated from the administration of a single dose of 
topically applied salicylic acid can be fitted to a 
biexponential equation. This equation can later be used to 
predict blood levels resulting from multiple doses of the 
drug. Equation 8 is a common form of the biexponential 
equation used to predict plasma concentrations. 
Equation ( 8) 
Where; 
t is the time measured from administration of 
the first dose 
t• is the time measured from administration 
of the nth dose 
( 
( 
n is the dose number 
"'ris the dosing interval 
k is the first order absorption rate constant 
K is the first order elimination rate constant 
Co is the initial drug concentration 
en is the concentration following the 
nth dose. 
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Peak plasma salicylic acid levels attained following 
the three hour application of SA ointment to stripped skin 
in a human volunteer were approximately 8 mg3 The entire 
arm is generally considered to represent nine percent of an 
individuals surface area (62). Therefore the area to which 
this ointment was applied, the forearm, represents 
approximately five percent of the total surface area of the 
volunteer. 
It is not uncommon for psoriatic patients to suffer 
lesions over at least thirty percent of their body (54). 
This represents a six fold increase in the area of skin 
exhibiting decreased barrier properties when compared to the 
condition created in human volunteers in the previous study. 
Application of SA ointment in the same manner as described 
for the normal human volunteers to the affected areas of 
psoriatics with thirty percent involvement would represent a 
six fold increase in the dose of salicylic acid applied. 
Equation 8 can be used to predict plasma salicylic acid 
( 
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concentrations in psoriatics applying SA ointment to 
involved skin totalling thirty percent of body surface area. 
Values of ke and ka used for this prediction are those 
obtained from the normal volunteer treated for three hours. 
The dose used was six times that used in the volunteer, 
corresponding to the six fold increase in the area of 
ointment application. The dosing interval, T, was every six 
hours. Figure 7 shows the predicted plasma salicylic acid 
versus time profile when the dosing regimen described above 
was carried out for forty eight hours. Steady state 
salicylic acid levels were attained after five doses and a 
concentration of approximately 60 mg% was predicted. This 
level is well above the lower level of toxicity, 20 tO 30mg. 
While the values of ka and ke used for this model were 
those obtained from only one experiment, it is probable that 
these values approximate those which would be seen in 
psoriatic patients, therefore, the predicted plasma 
concentrations appear reasonable. 
Although kinetic parameters have not been characterized 
in psoriatic patients, it is apparent from this work that 
patients treated chronically with salicylic acid containing 
ointments face the potential hazard of salicylate toxicity. 
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V. CONCLUSIONS 
1. Absorption and elimination rate constants for topically 
applied salicylic acid were calculated in rabbits and 
humans. 
species. 
Values obtained were of the same magnitude in both 
2. The addition of ten percent w/w urea to hydrophylic 
ointment containing ten percent salicylic acid had no 
significant effect on either the rate or extent of the 
systemic absorption of salicylic acid. 
3. Absorption of salicylic acid from hydrophylic ointment 
appeared to be complete in approximately six hours after 
initial application of the test ointment. 
4. Feeding of the test animals was found to cause a second 
peak in the plasma concentration versus time profile at a 
point approximately ten hours after the removal of the test 
ointment. The possibility of biliary recycling is 
discussed. 
5. Application of three percent salicylic acid in a 
polyethylene g2ycol/water vehicle showed no detectable 
absorption of salicylic acid, although marked keratolytic 
effect was observed. 
6. The application of ten percent salicylic acid in 
hydrophylic ointment to the skin of human volunteers with 
"normal" skin resulted in no detectable blood levels of 
( 
( 
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salicylic acid. The same ointment applied to volunteers 
whose skin had been stripped with adhesive tape resulted in 
plasma salicylic acid concentrations of approximately 8 mg 
percent. 
6. Application of the kinetic parameters calculated from 
human volunteers to multiple dosing regimens demonstrated 
the __ possibility of toxic levels of salicylic acid when 
a~piied topically every six hours over a twenty-four hour 
period. 
Future work 
Se.'veral possibilities for further investigation have 
·. r~Efn~ted from this work: 
r 1:. ,·.- TQ examine the possibility of biliary recycling of 
sal;~cy.lic . a·cid. This would be conducted by examining the 
effect ; ~f food on cthe release of bi~e into the duodenum • 
.. 
The · e.;f;f:et;;t .:· of preventing the secretion of bile into the 
duod~n~m~~ either by blocking the bile duct or cannulating 
the bladder and altering the flow of bile away from the 
duoden~m . will be studied. 
2. . To perform multiple dosing of topically applied 
salicylic aqid to determine the accuracy of predicted plasma 
concentrations and to examine the potential for attaining 
toxic lev.el.s in the plasma. 
~. To exa~ine the keratolytic activity of salicylic acid 
in high molecular weight polyethylene glycol ointment bases 
-... 
in order . to determine their 
therapeutically effective, 
polyethylene glycols may 
high 
therapeutic 
molecular 
efficacy. 
weight 
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If 
provide a vehicle 
preparations containing salicylic acid from 
systemic absorption would be minimal. 
for topical 
which the 
4. To characterize the pharmacokinetics of topically 
applied salicylic acid in the clinical setting, using 
psoriatic patients and in so doing to characterize the rate 
and extent of absorption of salicylic acid as a function of 
severity of disease state and types of psoriatic lesions 
involved. 
( 
( 
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Certification of Review 
and 
Special Implementation of Institutional Assurance 
The proposal titled "Study of Percutaneous Absorption of Salicylic Acid" 
submitted on behalf of Bruce K. Birmingham, J.W. Cooper - 1/5/76 has been 
reviewed by the assembled members of the IRB whose signatures below appear 
in accordance with the requirements of the DREW regulation of Protection of 
Human Subjects (45 CFR 46*). 
(1) ™iis IRB has determined that the subjects in this activity are at risk. 
The risks are: local skin irratation, Tinnitus and the possibility of in-
. fectio~ due to blood puncture • 
. (2) This IRB has determined to its satisfaction that the following saEe-
~uards against the specified risks are adequate: 
All subjects will be carefully screened before testing for broken 
skin or history of blood c ::.- ,;ula tion disorders, ulcers, or aspirin 
sensitivity. The tests wi:L be conducted in the University (Potter) 
Infirmary under the direc tion of an M.D., blood samples will be taken 
by a licensed medical laboratory technologist, utilizing the hest anti-
septic techniques. 
(3) This !RB has determined t o its satisfaction that the risks to the 
subjects are so outweighed ~y the sum of the benefits to the subject 
and the importance of the ~~owle<lge to be gained as to warrant a 
decision to allow the subject to accept the risks. This determination 
is based upon the following benefits or reasons: 
The risks involved are small since toxic hazard is both unlikely and 
of minor nature. 
(l;) This IRB has determined to its satisfaction that legally effective 
informed consent is to obtained and properly documented in accordance with 
the requirements specified ·in the regulation (45 CFR 46.3 (c) and 46.10). 
The informational statement to be given or read to each prospective sub-
ject before his participation in the activity is attached. 
(5) This I RB agrees to arrange for the continuing exchange of infornation 
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and advice between itself and the activity director on any matters affecting 
the rights and welfare of human subjects who participate in the activity. 
The specific instructions, advice, counsel and the conditions imposed by 
the !RB for the conduct of the activity are: 
.. - .:. 
. . , 
( 
( 
The next scheduled meeting of the !RB for review of this activity is 
December 1976. The IRB may be called into an interim review session by 
the Chairman at the request of any member, an institutional official or 
the project director to consider any matter concerned with the rights 
and welfare of any subject~ 
(6) This IRB has determined to its satisfaction that this institution 
will have available the professional attention and facilit i es that 
may be needed for subjects who may suffer physical, psychological or 
other injury as a result of participation in the activity. 
Christopher T. Rhodes, Ph.D. 
Profe r and Chairman 
~l 
M. Sage, Jr., Ph ;D. 
rorrdinator ~f ~rch ' 
~"}7 -1. : J {, l ,_ ( ·~ ....__ __ -
,:Joan M. Lausier, Ph.D. 
Assistant Professor 
. 
George c. Fuller, Ph.D. 
Associate Profes s or 
. \ 
,.~ -"" · ·--... .,..~ .- . ~ 
James R. Guthrie, X.D. 
Director, Clinical Servi ce 
t~\0n'\/Y?'~ :?~kr-
Demmie G. Mayfield, }yt. 
Chief of Psychiatry 
Veteran's Administration Hospital 
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Experimental Protocol 
Study of the Percutaneous Absorption of Salicylic Acid, College of Pharmacy 
University of Rhode Island 1976 
Investigators: 
Objectives: 
Bruce K. Birmingham, B.S. 
Graduate Student 
James W. Cooper, B.S., Ph.D. 
Assistant Professor and Director 
of Clinical Pharmacy 
Christopher T. Rhodes, B.Pharm., Ph.D. 
Professor and Chairman, Department of Pharmacy 
To examine and characterize the pharmacokinetics of salicylic 
acid absorption through the skin, in particular to define the rate 
and extent of drug absorption. An attempt to characterize inter-
patient variability will also be undertaken. 
yreliminary Screening of Subjects 
All those being considered for involvement in this study will be 
healthy volunteers between the ages of twenty and fifty, with no broken 
skin or history of blood coagulation disorders, ulcers or aspirin sensi-
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tivity. In addition, any other medical abnormality which in the opinion of 
the medical consultant or investigators is likely to complicate the study 
will result in exclusion from the study. All subjects will be carefully 
interviewed and pertinent medical information gathered. All participants 
will be provided the opportunity of reading and havinz carefully explained 
the Informed Consent Form. In addition, participants will be provided the 
opportunity for further questioning of the investigators. Any subjects may 
withdraw from the study at any time during the investigation. Participants 
will be required to abstain from aspirin containinp, products for one week 
prior to the test period and all drugs and alcohol for 43 hours prior to the 
test period. 
{ . 
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A one week "wash-out" period will be allowed between tests. 
The tests will be conducted in the University (Potter) Infirmary 
( under the direction of an M.D., blood samples will be taken by a 
licensed medical laboratory technologist. 
Salicylic acid will be supplied in the form of a buffered aqueous 
solution in which the subject will soak his arm for a period of two 
hours. Blood samples, to be drawn by a licensed medical laboratory 
technologist, will be taken inunediately preceeding immersion in the 
test solution and at the following times from the time of immersion, 
0.5 hours, 1.0, 1.5, 2.0, 4.0, and 3.0 hours. The test will require a 
lOml sample to be taken at each interval, for a total of 70mls of 
blood from each volunteer for each test. Participants will also be 
asked to provide a urine sample twenty-four hours following application 
of the test solution. 
Minimum toxic levels of salicylic acid have been reported at be-
tween 20 and 40rngi.. The current study is designed so that serum sali-
cylate levels do not exceed lOmgi.. 
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Investigators: Bruce K. Birmingham, B.S. 
James W. Cooper, B.S., Ph.D. 
Assistant Professor and Director of Clinical Pharmacy 
( Christopher T. Rhodes, Ph.D. 
( 
Professor and Chairman of Pharmacy 
Salicylic acid is a drug used in the treatment of several types of skin 
disorders. It is normally supplied to the patient in the form of an ointment 
or cream which is applied topically (i.e., directly to the affected areas of 
the skin.) 
The objective of this research project is to study the absorption 
characteristics of salicylic acid when applied to normal volunteers in the 
form of an aqueous (water) solution. 
Should you volunteer to participate in this project you will be required 
to abstain from all drugs and alcohol for a period of 48 hours prior to each 
test, as well as abstaining from all aspirin containing compounds for one week 
prior to the beginning of the test period and for the duration of the study, 
approximately ten weeks. The test solution will be prepared by the investigators 
and will contain 3% salicylic acid in water. You will be asked to place your arm 
in a bath containing the test solution for a period of two hours. Blood samples 
will be taken during the course of topical application and at four and eight hours 
after the start of the test. You will be asked to supply urine samples for a 
period of 2'• hours following each treatment. 
The possible effect of the salicylic acid test solution application is local 
skin irritation at the site of application of the test solution. Tinnitus (i.e., 
a ringing sensation in the ears) is the first sign of toxicity which rarely 
occurs .below salicylate levels of 20mg%. This study is designed not to exceed 
levels of 10mg%. 
Should you volunteer for this project you will be free to withdraw from 
participation at any time during the investigation. You will not be i dentified 
in any publication resulting from this work. 
·r, having carefully read and understood the above 
and having been given the opportunity of asking questions regarding the above 
project now give my informed consent to participation in the Study of the Percu-
taneous Absorption of Salicylic Acid, University of Rhode Island. 
Date 
Signed 
Witness 
